Shares of Jaguar Health, Inc. (NASDAQ:JAGX) recorded -8.77% loss during trading session on April 15th, 2019. The script traded as low as $0.22 and last traded at $0.22. 6.5 million shares changed exchanged hands during trading, an increase of 1.19% from the 30-day average session volume of 6.58M shares. The firm had previously closed at $0.24. The company has $76.90M outstanding shares, price-to-earnings-growth ratio of 3.89and a beta of 1.25. The company has a RSI of 41.58, ATR of 0.05 and a volatility of 9.46% this week. JAGX has a 52 week low price of $0.12 and a 52 week high price of $3.20.

Investors have identified the tech company Jaguar Health, Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around 17.11M, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.

Jaguar Health, Inc. (JAGX) Fundamentals that are to be considered.

When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For JAGX, the company has in raw cash 2.57 million on their books with 4.94 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on an incline. In terms of their assets, the company currently has 0 total, with 0 as their total liabilities. This figure have given the company a good sense of viability under numerous contexts.

JAGX were able to record 22.74 million as free cash flow during the recently reported quarter of the year, this saw their quarterly net cash flow reduce by 1.81 million. In cash movements, the company had a total of 22.73 million as operating cash flow.

Potential earnings growth for Jaguar Health, Inc. (JAGX)

In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the third quarter of the year, Jaguar Health, Inc. recorded a total of 1.6 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 0.03% coming in sequential stages and their sales for the third quarter increasing by 0.29%.

What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 957000 trying to sell their products during the last quarter, with the result yielding a gross income of 639000. This allows shareholders to hold on to 76.90M with the revenue now reading -350 cents per share.

Is the stock of JAGX attractive?

In related news, Director Siegel Jonathan B. bought 25,000 shares of the company’s stock in a transaction that recorded on October 4th, 2019. The purchase was performed at an average price of 0.60, for a total value of 15,000. As the purchase deal closes, the 10% Owner Siegel Jonathan B. now sold 325,615 shares of the company’s stock, valued at 595,875. Also, CEO and President CONTE LISA A bought 1,500 shares of the company’s stock in a deal that was recorded on July 18th, 2019. The shares were bought at an average cost of 1.11 per share, with a total market value of 7,500. Following this completion of disposal, the Director now holds 5,000 shares of the company’s stock, valued at 5,476. In the last 6 months, insiders have changed their ownership in shares of company stock by 9.57%.